Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAPOR-C: Anesthesia Impact on Cancer Recurrence
NCT04316013Phase 3Terminated
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jul 2020
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, single-blind trial of propofol injection (veterinary) and Lidocaine Hydrochloride Injection, without epinephrine in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) (4 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Disease Free Survival at 3 years. Started Jul 2020; status: terminated.
02
Drugs
propofol injection (veterinary)Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04316013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316013.